<DOC>
	<DOCNO>NCT02511288</DOCNO>
	<brief_summary>The goal project create biological collection blood sample patient advanced stage IIIB/IV non-small cell lung cancer ( NSCLC ) clinical annotation .</brief_summary>
	<brief_title>LIquid BIopsies Lung Cancer ( LIBIL )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>COHORT 1 Patients histologically confirm advanced nonsmallcell lung carcinoma ( stage IIIB/IV ) regardless mutation status Inclusion time diagnostic Realization tumor biopsy institution ( Centre Léon Bérard ) outside institution available histopathological report Age ≥ 18 year Patients treat liquid biopsy COHORT 2 Inclusion criterion Patients histologically confirm advanced nonsmallcell lung carcinoma ( stage IIIB/IV ) one follow molecular anomaly : Epidermal Growth Factor Receptor ( EGFR ) , BRaf proto oncogene ( BRAF ) Human Epidermal Growth Factor Receptor2 ( HER2 ) mutation , Anaplatsic Lymphoma Kinase ( ALK ) ROS portooncogene 1 ( ROS1 ) translocation , Mesenchymalepithelial transition factor ( MET ) amplification , RET rearrangement . Inclusion time diagnostic followup relapse Realization tumor biopsy institution ( Centre Léon Bérard ) outside institution available histopathological report Age ≥ 18 year Exclusion criteria Patients treat liquid biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hematologic test</keyword>
</DOC>